TNF Pharmaceuticals is set to initiate fully funded mid-stage Phase II clinical trials of its lead programme, MYMD-1, targeting sarcopenia.
MYMD-1, a small molecule therapy, has shown positive results in regulating the immuno-metabolic system by blocking TNF-alpha activity.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The upcoming studies aim to build on the positive results from an earlier Phase II trial, which demonstrated MYMD-1’s efficacy in reducing chronic inflammation markers in sarcopenia / frailty.
TNF Pharmaceuticals president and chief medical officer Mitchell Glass said: “In our view, MYMD-1, if approved, could be the first orally administered TNF-alpha inhibitor drug and the first and only therapy for sarcopenia, a common age-related disorder that causes a prolonged decline in physical function.
“As we prepare for our next fully funded clinical studies in sarcopenia/frailty, we also have open INDs for Phase II trials of MYMD-1 in two additional chronic inflammatory conditions, rheumatoid arthritis (RA) and Hashimoto’s thyroiditis, which we could pursue with the support of non-dilutive domestic and/or international development partnerships.
“A partner outside of the US could potentially help us accelerate the timeline to commercialisation of our lead asset.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMYMD-1 targets TNF-alpha, a key protein in inflammation and autoimmunity.
A small Phase II study that was concluded last year showed that it significantly reduced serum levels of chronic inflammatory markers, without any treatment-related adverse events.
The drug’s ability to cross the blood-brain barrier also positions it as a potential treatment for rheumatoid arthritis and Hashimoto’s thyroiditis.
MYMD-1’s reduction of inflammation biomarkers, including TNF-α, sTNFR1, and IL-6, marks a significant step forward in addressing sarcopenia.
TNF Pharmaceuticals also has a secondary drug platform, Supera-CBD, a synthetic CBD analogue.
Supera-CBD is being developed for pain, epilepsy, anxiety and depression, and potentially opioid addiction treatment, given its binding profile with opioid receptors.
